Table 3 Organ dysfunction in individual patients
From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
| Baseline organ dysfunction | Baseline measurements | Worsening dysfunction (grade) |
|---|---|---|
| Renal and hepatic | Creatinine 2.6, cirrhosis on imaging | Edema (1) |
| Renal | Creatinine 3.0 | Acute kidney injury (2) |
| Renal | Creatinine 2.2 | Ascites (3) |
| Renal | Creatinine 4.6 | Acute kidney injury (1) |
| Renal and cardiac | Creatinine 2.6, Ejection fraction 40 % | Acute kidney injury (1), volume overload (3) |
| Cardiac | Ejection fraction 30 % | Decompensated heart failure (3) |
| Cardiac | Ejection fraction 20 % | Decompensated heart failure (3) |
| Liver and cardiac | Ejection fraction 45 %, cirrhosis on imaging | Volume overload and decompensated heart failure (3) |